ASH China Voice | Prof. Yajing Zhang: Exploring Frontiers and Synergistic Innovation—A Multidimensional and Strategic Vision for CAR-T Therapy

ASH China Voice | Prof. Yajing Zhang: Exploring Frontiers and Synergistic Innovation—A Multidimensional and Strategic Vision for CAR-T Therapy

2025.12.22
The 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando from December 6 to 9, 2025, bringing together the latest global advances in hematologic research and clinical practice. At this year’s meeting, four studies led by Prof. Yajing Zhang from Beijing Gobroad Boren Hospital were accepted, including one oral presentation.
“Six Fewer Needles*!” — Peking University First Hospital Reports Breakthrough in Precision Prostate Biopsy, Published in The Lancet Sub-Journal

“Six Fewer Needles*!” — Peking University First Hospital Reports Breakthrough in Precision Prostate Biopsy, Published in The Lancet Sub-Journal

2025.12.14
On November 14, a research team led by Prof. Kan Gong and Associate Chief Physician Yi Liu from the Department of Urology, Peking University First Hospital and the Institute of Urology, Peking University, published a major advancement in precision prostate biopsy in eClinicalMedicine, a sub-journal of The Lancet.
Professor Ning-NingLu: Precision Radiotherapy in Urologic Malignancies: State-of-the-Art Clinical Practices and Emerging Strategies

Professor Ning-NingLu: Precision Radiotherapy in Urologic Malignancies: State-of-the-Art Clinical Practices and Emerging Strategies

2025.12.12
With China’s population undergoing demographic aging and growing public awareness of cancer screening, the clinical need for the management of urologic malignancies is steadily increasing. Radiotherapy, a mainstay of oncologic treatment, has evolved rapidly—progressing from old techniques to intensity‑modulated radiotherapy (IMRT), and from conventional fractionation regimens to stereotactic body radiation therapy (SBRT). Precision radiotherapy is now emerging as a pivotal modality in the management of urologic cancers. Professor Ningning Lu, affiliated to the National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, has dedicated years to the field of precision radiotherapy for urologic tumors, amassing substantial clinical expertise and a robust research portfolio. UroStream invited Professor Lu to deliver an in-depth review of the clinical applications of precision radiotherapy in urologic malignancies, thereby providing evidence-based insights and practical guidance for clinicians.